Global Healthcare Analyst

Tina Banerjee

Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/venus-medtech-hangzhou-inc" target="_blank" data-smartkarma-citation="entities:28257:1" rel="noopener">Venus MedTech (2500 HK)</a> is facing competition in China TAVR market and its market share has deteriorated to 70% in 2021 from 79.3% in 2018.</li>
<li>Due to declining ASP and low pricing power, the company’s gross profit margin has declined to 78% in 2021 from 86% in 2018.</li>
<li>During 2021, the company’s loss expanded 103% y/y to RMB372 million, mainly due to elevated selling and distribution expenses and R&amp;D costs.</li>
</ul>



Venus MedTech (2500 HK) is facing competition in China TAVR market and its market share has deteriorated to 70% in 2021 from 79.3% in 2018.
Due to declining ASP and low pricing power, the company’s gross profit margin has declined to 78% in 2021 from 86% in 2018.
During 2021, the company’s loss expanded 103% y/y to RMB372 million, mainly due to elevated selling and distribution expenses and R&amp;D costs.


Venus MedTech (2500 HK): Overcrowded Market, Margin Pressure, Expanding Loss

Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Capital Markets

Boston Scientific / Equity Capital Markets

<ul><li>Boston Scientific's third-quarter results were impacted by the coronavirus more than anticipated as the new variants surged globally and some electric procedures were deferred.</li><li>The company’s third-quarter operational revenues increased by 10% compared to 2020, while organic sales increased by 11% compared to 2020 and 4% compared to 2019.</li><li>Despite the short-term impact of procedure volumes, Boston Scientific witnessed momentum in new product launches, generated strong clinical evidence, and performed broadly across the portfolio.</li></ul>

Boston Scientific's third-quarter results were impacted by the coronavirus more than anticipated as the new variants surged globally and some electric procedures were deferred.The company’s third-quarter operational revenues increased by 10% compared to 2020, while organic sales increased by 11% compared to 2020 and 4% compared to 2019.Despite the short-term impact of procedure volumes, Boston Scientific witnessed momentum in new product launches, generated strong clinical evidence, and performed broadly across the portfolio.

Boston Scientific Corporation - Investment Thesis

Scivita Medical Technology / Equity Capital Markets

<ul>
<li>
<a href="https://www.smartkarma.com/entities/scivita-medical-technology" target="_blank" data-smartkarma-citation="entities:34701:1" rel="noopener">Scivita Medical Technology (SMT HK)</a> mainly focuses on single-use medical endoscopes, which comprises of three approved products and 11 pipeline products.</li>
<li>Global single-use medical endoscope market is a limited competition market, with high growth potential. The risk of contamination will continue to be the key driver of single-use endoscopes.</li>
<li>Scivita is at its early stage of commercialization in China and overseas market. Technical features of Scivita single-use endoscopes are comparable or superior to industry leader Ambu. </li>
</ul>



Scivita Medical Technology (SMT HK) mainly focuses on single-use medical endoscopes, which comprises of three approved products and 11 pipeline products.
Global single-use medical endoscope market is a limited competition market, with high growth potential. The risk of contamination will continue to be the key driver of single-use endoscopes.
Scivita is at its early stage of commercialization in China and overseas market. Technical features of Scivita single-use endoscopes are comparable or superior to industry leader Ambu. 


Scivita Medical Technology (SMT HK) Pre-IPO: A Promising Game Changer with First-Mover Advantage

<ul>
<li>
<a href="https://www.smartkarma.com/entities/abbott-laboratories" target="_blank" data-smartkarma-citation="entities:11987:1" rel="noopener">Abbott Laboratories' (ABT US)</a> diversified business mix continued to prove highly resilient even during the worst period of pandemic. Strong consumer-facing and diagnostic businesses mitigated the slump in hospital-related business.</li>
<li>Dominant positioning in the Covid-19 diagnostic should augur well during the emergence of Omicron variant. Double-digit growth in non-Covid diagnostics portfolio enhances conviction in post-Covid era.   </li>
<li>Existing leadership positioning and multiple new product launches in large and high-growth market segments, including structural heart and diabetes remain long-term growth driver for Abbott.</li>
</ul>



Abbott Laboratories' (ABT US) diversified business mix continued to prove highly resilient even during the worst period of pandemic. Strong consumer-facing and diagnostic businesses mitigated the slump in hospital-related business.
Dominant positioning in the Covid-19 diagnostic should augur well during the emergence of Omicron variant. Double-digit growth in non-Covid diagnostics portfolio enhances conviction in post-Covid era.   
Existing leadership positioning and multiple new product launches in large and high-growth market segments, including structural heart and diabetes remain long-term growth driver for Abbott.


2022 High Conviction: Abbott Laboratories – Resilient Business Model at Reasonable Valuation

<ul><li>Boston Scientific has recently been in the news for its $1.75 billion acquisition of Baylis Medical.</li><li>The company reported outstanding Q2 financial results with a staggering 50% groth in operational sales as compared to 2020.</li><li>Overall, we are optimistic about Boston Scientific and give it an ‘Outperform’ rating on the stock with a revised target price.</li></ul>

Boston Scientific has recently been in the news for its $1.75 billion acquisition of Baylis Medical.The company reported outstanding Q2 financial results with a staggering 50% groth in operational sales as compared to 2020.Overall, we are optimistic about Boston Scientific and give it an ‘Outperform’ rating on the stock with a revised target price.

United States

Boston Scientific Corporation develops, manufactures, and markets minimally invasive medical devices. The Company's products are used in interventional cardiology, cardiac rhythm management, peripheral interventions, electrophysiology, neurovascular intervention, endoscopy, urology, gynecology and neuromodulation.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Boston Scientific (BSX US)

Venus MedTech (2500 HK): Overcrowded Market, Margin Pressure, Expanding Loss

Despite shares plunged 82% from highs, Venus MedTech is not a bottom-fishing idea, as unfavorable competitive landscape in its operating market...

Tina Banerjee

Boston Scientific Corporation - Investment Thesis

Boston Scientific's third-quarter results were impacted by the coronavirus more than anticipated as the new variants surged globally and some...

Baptista Research

Scivita Medical Technology (SMT HK) Pre-IPO: A Promising Game Changer with First-Mover Advantage

With its comprehensive endoscopic product portfolio and expanding commercialization capabilities, Scivita is well-positioned to capture the huge...

Tina Banerjee

2022 High Conviction: Abbott Laboratories – Resilient Business Model at Reasonable Valuation

With pandemic-resistant diversified business model, Abbott is well-positioned for high single-digit long-term revenue growth.

Tina Banerjee

Boston Scientific Corporation - Investment Thesis

Boston Scientific has recently been in the news for its $1.75 billion acquisition of Baylis Medical. The company reported outstanding Q2 financial...

Baptista Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)